Cerus Corporation: FY2023 Form 10-K Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated blood components. The fiscal year ended December 31, 2023; the filing provides annual results rather than a separately reported fourth-quarter income statement.
- Commercial products include pathogen-reduction systems for platelets and plasma, INTERCEPT Fibrinogen Complex and related cryoprecipitation products.
- The red blood cell system remains in development and has not been commercialized.
- Products are sold directly and through distributors across North America, Europe, the Middle East, the Commonwealth of Independent States and selected other markets.
Financial performance and key metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $186.8 million | $188.3 million | Down 1% |
| Product revenue | $156.4 million | $162.0 million | Down 4% |
| Government contract revenue | $30.4 million | $26.3 million | Up 16% |
| Gross profit on product revenue | $86.4 million | $87.1 million | Down 1% |
| Product gross margin | 55% | 54% | Up 1 percentage point |
| Loss from operations | $(30.1) million | $(34.1) million | Improved |
| Net loss attributable to Cerus | $(37.5) million | $(42.8) million | Improved |
| Basic and diluted loss per share | $(0.21) | $(0.24) | Improved |
| Net cash used in operating activities | $(43.2) million | $(25.6) million | Use increased |
Approximate total-revenue operating margin was negative 16%, and approximate net margin was negative 20%. The company continues to operate at a loss.
- Product revenue declined primarily because U.S. customers reduced disposable platelet-kit inventories following the FDA-related reduction in U.S. shelf life to six months.
- Research and development expense increased 6% to $67.6 million, driven by the next-generation illuminator and increased clinical activity.
- Selling, general and administrative expense decreased 9% to $75.5 million, primarily due to workforce reductions and lower stock-based compensation.
- Interest expense increased 44% to $8.4 million as borrowing levels and interest rates increased.
- Restructuring charges were $3.7 million, including workforce-reduction and facilities-consolidation costs.
Liquidity, debt and capital resources
| Balance-sheet metric | December 31, 2023 | December 31, 2022 |
|---|---|---|
| Cash and cash equivalents | $11.6 million | $35.6 million |
| Short-term investments | $54.2 million | $66.6 million |
| Cash, investments and restricted cash | $67.6 million | $103.9 million |
| Total debt | $79.8 million | $69.8 million |
| Working capital | $78.4 million | $53.1 million |
| Total inventory | $59.4 million | $44.5 million |
- Operating cash use exceeded $43 million in 2023, while financing activities provided $10.7 million.
- Debt consisted of a $60.0 million term loan and a $20.0 million revolving loan. The company was in compliance with stated debt covenants at year-end.
- The term loan bears interest at Term SOFR plus 6.50%, subject to a 1.00% floor; the stated rate at year-end was approximately 12.2%.
- Term-loan principal amortization is scheduled to begin in 2026 unless the facility is restructured or the interest-only period is extended by meeting specified revenue conditions.
- The company states that available cash, short-term investments, product receipts and government-contract reimbursements should meet capital requirements for at least the next 12 months, but cautions that this depends on assumptions that may prove incorrect.
- The company had approximately $96.8 million available under its at-the-market equity sales agreement at year-end, but sold no shares under that agreement during 2023.
Material changes versus the prior comparable period
- Total revenue was broadly stable, but the mix shifted toward government-contract revenue and away from product revenue.
- Operating loss narrowed by approximately $4.0 million, and net loss narrowed by approximately $5.3 million.
- Cash, investments and restricted cash declined by approximately $36.4 million, while operating cash use increased by approximately $17.6 million.
- Total debt increased by approximately $10.0 million, with a substantial portion reclassified from current to non-current under amended credit agreements.
- Inventory increased by approximately $14.9 million, reflecting efforts to secure supply and support anticipated demand.
- The company implemented a restructuring plan, reduced its workforce by approximately 10% and ceased using approximately 15,000 square feet of office space.
- In December 2023, Cerus received MDR CE Certificates of Conformity for its platelet and plasma systems, allowing continued European Union commercialization.
- In May 2023, the DoD increased the value of its lyophilized cryoprecipitate contract from $9.1 million to $17.8 million and extended it to February 2027.
- BARDA committed funding of up to $185.5 million as of year-end, with a potential total funding opportunity of up to $270.2 million through September 2026, subject to options, milestones and government discretion.
Guidance, outlook, commentary and risks
- Management expects product revenue to grow in future periods, supported by increased platelet adoption and commercialization in additional geographies, but does not anticipate government-contract revenue will materially increase.
- 2024 commercial priorities include increasing platelet and plasma production at existing customers, expanding cryoprecipitation kit and IFC sales, and developing market awareness.
- Management expects a decision on the European MDR certification application for the red blood cell system in the second half of 2024, while emphasizing that timing and approval are uncertain.
- The ReCePI red blood cell Phase 3 trial completed enrollment; top-line data were expected later in the first quarter of 2024. The RedeS study remains ongoing.
- Red blood cell development faces regulatory, manufacturing and clinical risks, including treatment-emergent antibodies, potential hemolysis, additional data requirements and a dispute with a sole supplier of key components.
- IFC commercialization remains constrained because additional blood-center manufacturing partners need FDA site-specific licenses or BLAs. Three partners had received BLAs at year-end.
- Cerus relies heavily on third parties, including Fresenius as the primary supplier of platelet and plasma disposable kits, and has limited qualified alternatives for several components.
- The next-generation illuminator requires regulatory approval; shortages of current-model illuminators or spare parts could limit sales and customer support.
- Product adoption depends on concentrated blood-center customers, reimbursement, customer validation, operational compatibility and the company’s ability to expand its commercial organization.
- The Department of Justice Antitrust Division issued a civil investigative demand concerning contracting and information-exchange practices. The company states that no claim or proceeding had been initiated as of the filing date, but the investigation remains unresolved.
- Other risks include continued losses, possible need for additional capital or dilution, interest-rate exposure, foreign-exchange volatility, supply-chain disruption, product liability, regulatory enforcement, cybersecurity incidents, intellectual-property disputes and geopolitical effects on international sales.
Most important facts for investors to verify
- Whether platelet-kit revenue rebounds after U.S. inventory reductions and the six-month shelf-life constraint.
- Actual cash burn and liquidity runway relative to management’s stated 12-month sufficiency assessment.
- Availability and terms of additional BARDA option funding and achievement of required clinical milestones.
- Results of the ReCePI and RedeS trials, treatment-emergent antibody events and the path toward U.S. red blood cell approval.
- Timing and outcome of the MDR certification process for the red blood cell system.
- Progress in obtaining additional IFC BLAs and whether manufacturing capacity can support nationwide demand.
- Fresenius and other supplier capacity, alternate-source qualification and the status of the redesigned illuminator.
- Terms, compliance requirements and repayment implications of the company’s secured debt, including scheduled principal amortization beginning in 2026.
- Developments in the DOJ Antitrust Division investigation and any related financial, operational or reputational consequences.
- Customer concentration: the American Red Cross represented 35% of 2023 product revenue and Établissement Français du Sang represented 12%.